{"meshTags":["Melanoma","Neoplasm Staging","Humans","Survival Rate","Lymph Node Excision","Adolescent","Skin Neoplasms","Lymphatic Metastasis","Aged, 80 and over","Disease Progression","Female","Adult","Aged","Middle Aged","Retrospective Studies","Prognosis","Male"],"meshMinor":["Melanoma","Neoplasm Staging","Humans","Survival Rate","Lymph Node Excision","Adolescent","Skin Neoplasms","Lymphatic Metastasis","Aged, 80 and over","Disease Progression","Female","Adult","Aged","Middle Aged","Retrospective Studies","Prognosis","Male"],"organisms":["6755"],"publicationTypes":["Journal Article"],"abstract":"To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy.\nRetrospective study.\nSpecialist hospital, USA.\n130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992.\nSurvival and prognostic factors on multivariate analysis.\nFour factors were independent prognostic indicators for patients with stage III malignant melanoma: age \u003e51 years (p \u003d 0.008), \u003e3 involved lymph nodes, (p \u003d 0.03), the site of the primary tumour on head or trunk, (p \u003d 0.007), and the presence of palpable lymph nodes (p \u003d 0.004).\nThese prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.","title":"Prognostic variables for patients with stage III malignant melanoma.","pubmedId":"10755339"}